Telix reports 19% Q3 revenue growth, FDA approval for Pixclara and announces $1.65 bn ITM merger
Telix Pharmaceuticals announced third‑quarter 2026 group revenue of $245 million, up 19% year‑over‑year, with Precision Medicine revenue of $201 million, up 30%. The U.S. FDA approved its glioma imaging agent Pixclara and the company disclosed a merger with Isotope Technologies Munich (ITM) for $1.65 billion upfront plus up to $700 million contingent consideration. Telix reaffirmed FY 2026 revenue guidance of $950 million‑$970 million and said total revenue and other income for the year should exceed $1 billion.
Why it matters
The strong revenue growth and FDA approval support the outlook, but the merger announcement triggered a near‑10% drop in TLX shares as investors worry about dilution and ITM’s recent FDA manufacturing issue. The FY 2026 guidance above $950 million signals the company expects to surpass the $1 billion revenue threshold, which could influence valuation models.
Key facts
- 1Group revenue was $245 million, a 19% increase from the prior year. stocktitan.net
- 2Precision Medicine revenue was $201 million, a 30% increase from the prior year. stocktitan.net
- 3The FDA approved Pixclara for glioma imaging. stocktitan.net
- 4Telix announced a merger with ITM for $1.65 billion upfront, plus up to $700 million contingent. ibtimes.com.au
- 5FY 2026 revenue guidance was reaffirmed at $950 million‑$970 million. stocktitan.net
- 6Telix expects total revenue and other income for FY 2026 to exceed $1 billion. stocktitan.net
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.